PMPRB Summary of VCUs & Orders - 2005

Click on medicine to view details of VCU

DATE OF APPROVAL MEDICINE PATENTEE %Above Guidelines PRICE REDUCTION1 EXCESS REVENUES2 PAYMENTS PATENT STATUS
VCUs
Dec 15, 2005 Risperdal Janssen-Ortho Inc. Yes See VCU for details $669,426.81 $669,426.81 Expired 07/2006
Dec 15, 2005 DukoralTM sanofi pasteur Limited Yes See VCU for details $481,198.49 $481,198.49 Expiration 06/2016
Sept 9, 2005 Ortho 7/7/7 Ortho Inc. Yes
$99,892.72 $99,892.72 Expired 09/2004
July 25, 2005 Starlix Novartis Pharma Yes 2005 MNE: $0.5044 $174,306.29 $174,306.29 Expiration 02/2014
July 14, 2005 Ceretec Amersham Health Inc. Yes 2005 MNE: 177.7475; 2004: 173.1935 $278,112.658
Expired 04/2006
Mar 7, 2005 Paxil CR GlaxoSmithKline Inc.
MNE: $1.5861/12.5 mg; $1.7019/25 mg $ 310,403.64 $ 310,403.64 Expiration 07/2016
Mar 7, 2005 Tamiflu Hoffmann-La Roche Limited
2005 MNE: $3.8917/per 75 mg caps $442,973.47 $442,973.47 Expired 05/2019
Feb 17, 2005 Evra9 Janssen-Ortho Inc. Yes Yes $4.47 Patch reduction of 45% $300,00.0010 $1,359,263.67 Expiration 08/2014 and 06/2016
ORDER

1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.

2. In all cases, all excess revenues were offset through further price reduction and/or payment.

8. In the event any excess revenues had not been offset by the end of 2005, Amersham was to make a payment to each of the customers that purchased Ceretec from January 1, 2002 to December 31, 2004. Payments totaling $12,326.31 were made to offset the remaining excess revenues.

9. Notice of Hearing issued on December 23, 2004.

10. Excess revenues in the Evra matter were offset through 1) payment to the Government of Canada of $1,359,263.67; and 2) the remainder, $1,496,019.02, were offset through price reduction of Levaquin, another patented medicine sold by Janssen-Ortho in Canada, and a further payments to the Government of Canada in the amount of 683,272.00.

Date modified: